Directing systemic oncolytic viral delivery to tumors via carrier cells

Hiroshi Nakashima; Balveen Kaur; E. A. Chiocca

doi:10.1016/j.cytogfr.2010.02.004

Directing systemic oncolytic viral delivery to tumors via carrier cells

Hiroshi Nakashima, Balveen Kaur, E. A. Chiocca

Research output: Contribution to journal › Review article › peer-review

60 Scopus citations

Abstract

The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the virus from host defenses and direct them toward tumors: Mesencymal and neural stem cells have been described to possess tumor-homing ability as well as the capacity to deliver OVs. In this review, we will focus on approaches where OV and carrier cells are utilized for cancer therapy. Effective cellular internalization and replication of OVs need to occur both in cancer and carrier cells. We thus will discuss the current challenges faced by the use of OV delivery via carrier cells.

Original language	English (US)
Pages (from-to)	119-126
Number of pages	8
Journal	Cytokine and Growth Factor Reviews
Volume	21
Issue number	2-3
DOIs	https://doi.org/10.1016/j.cytogfr.2010.02.004
State	Published - Apr 2010
Externally published	Yes

Keywords

Adenovirus
Carrier cells
HSV-1
MSC
NSC
Virus delivery

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Immunology and Allergy
Immunology
General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cytogfr.2010.02.004

Cite this

@article{c5506d5c2bc041b7a4358f59ecc62088,

title = "Directing systemic oncolytic viral delivery to tumors via carrier cells",

abstract = "The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the virus from host defenses and direct them toward tumors: Mesencymal and neural stem cells have been described to possess tumor-homing ability as well as the capacity to deliver OVs. In this review, we will focus on approaches where OV and carrier cells are utilized for cancer therapy. Effective cellular internalization and replication of OVs need to occur both in cancer and carrier cells. We thus will discuss the current challenges faced by the use of OV delivery via carrier cells.",

keywords = "Adenovirus, Carrier cells, HSV-1, MSC, NSC, Virus delivery",

author = "Hiroshi Nakashima and Balveen Kaur and Chiocca, {E. A.}",

note = "Funding Information: This work was supported by funding from the National Institutes of Health Grant K01NS059575 ; R01NS064607 ; R21NS056203 to BK, and R21NS0632901 ; U01 NS061811 ; P01 CA069246 to EAC. ",

year = "2010",

month = apr,

doi = "10.1016/j.cytogfr.2010.02.004",

language = "English (US)",

volume = "21",

pages = "119--126",

journal = "Cytokine and Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier BV",

number = "2-3",

}

TY - JOUR

T1 - Directing systemic oncolytic viral delivery to tumors via carrier cells

AU - Nakashima, Hiroshi

AU - Kaur, Balveen

AU - Chiocca, E. A.

N1 - Funding Information: This work was supported by funding from the National Institutes of Health Grant K01NS059575 ; R01NS064607 ; R21NS056203 to BK, and R21NS0632901 ; U01 NS061811 ; P01 CA069246 to EAC.

PY - 2010/4

Y1 - 2010/4

N2 - The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the virus from host defenses and direct them toward tumors: Mesencymal and neural stem cells have been described to possess tumor-homing ability as well as the capacity to deliver OVs. In this review, we will focus on approaches where OV and carrier cells are utilized for cancer therapy. Effective cellular internalization and replication of OVs need to occur both in cancer and carrier cells. We thus will discuss the current challenges faced by the use of OV delivery via carrier cells.

AB - The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the virus from host defenses and direct them toward tumors: Mesencymal and neural stem cells have been described to possess tumor-homing ability as well as the capacity to deliver OVs. In this review, we will focus on approaches where OV and carrier cells are utilized for cancer therapy. Effective cellular internalization and replication of OVs need to occur both in cancer and carrier cells. We thus will discuss the current challenges faced by the use of OV delivery via carrier cells.

KW - Adenovirus

KW - Carrier cells

KW - HSV-1

KW - MSC

KW - NSC

KW - Virus delivery

UR - http://www.scopus.com/inward/record.url?scp=77953537092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953537092&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2010.02.004

DO - 10.1016/j.cytogfr.2010.02.004

M3 - Review article

C2 - 20226717

AN - SCOPUS:77953537092

SN - 1359-6101

VL - 21

SP - 119

EP - 126

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

IS - 2-3

ER -

Directing systemic oncolytic viral delivery to tumors via carrier cells

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this